Dr Michael Rosenblatt
Michael Rosenblatt, M.D., has held major leadership roles in academia and the biopharmaceutical industry, and currently serves as Senior Partner of Flagship Pioneering in Cambridge, MA. Dr. Rosenblatt was Chief Medical Officer (CMO) for Merck from 2009-2016. Earlier (his first of two times at Merck), he was SVP for Research at Merck Research Laboratories where he co-led the development of alendronate (FOSAMAX), now the leading therapy worldwide for osteoporosis. Additionally, he directed drug discovery efforts in molecular biology, bone biology, virology, cancer research, gastroenterology, ophthalmology, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy.
He has been an active participant in the biotechnology industry, serving on the board of directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, the company that discovered bortezomib (Velcade), now Takeda’s drug for multiple myeloma and other malignancies, and Radius Pharmaceuticals, a women’s health company. He was also a member of the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. Dr. Rosenblatt currently is a member of the Harvard Medical School (HMS) Board of Fellows, the Tufts Graduate School of Biomedical Sciences Dean’s Advisory Committee, and on research advisory committees of the Massachusetts General Hospital, Brigham and Women’s Hospital, and Children’s Hospital (Boston). He is a member of the Board of Directors of Azenta Life Sciences, Rubius Therapeutics, as well as several biotech start-ups. Dr. Rosenblatt also contributed to Moderna’s coronavirus vaccine efforts as a member of Moderna’s Development Committee, Vaccine Acceleration Committee, chairman of the Vaccine Ethics and Access Committee and as a special consultant to the CMO.
Dr. Rosenblatt received his undergraduate degree summa cum laude from Columbia University and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.